Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal initiation strategy for adalimumab and methotrexate in early rheumatoid arthritis
2006-004139-31Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of adalimumab and methotrexate in rheumatoid arthritis (RA) (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Primary efficacy endpoint. Started Dec 2006; status: completed.
02
Drugs
adalimumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-004139-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004139-31.